The effects of flavonoids on the ABC transporters: Consequences for the pharmacokinetics of substrate drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 3, 2013, Pages 267-285

  Li, Yan ^a   Paxton, James W ^b  

^a AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

ABC transporters; Breast cancer resistance protein; Flavonoids; Multidrug resistance protein 1; Multidrug resistance protein 2; P glycoprotein

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE; APIGENIN; AURANTIIN; CATECHIN; CHALCONE; CHRYSIN; EPIGALLOCATECHIN GALLATE; FLAVANOL DERIVATIVE; FLAVANONE; FLAVONE; FLAVONOID; FLAVONOL; GLUCURONIDE; ISOFLAVONE; LUTEOLIN; MORIN; MYRICETIN; NARINGENIN; PINOCEMBRINE; QUERCETIN;

CATALYSIS; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ENZYME ACTIVITY; LIPID MEMBRANE; REVIEW;

ADENOSINE TRIPHOSPHATE; ADMINISTRATION, ORAL; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CARRIER PROTEINS; DIET; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; DRUG RESISTANCE; FLAVONOIDS; HUMANS; HYDROLYSIS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; XENOBIOTICS;

EID: 84874081668     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.749858     Document Type: Review

References (153)

1. Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2008;88(1):38-50 (Pubitemid 351988681)
2. Dembinska-Kiec A, Mykkanen O, Kiec-Wilk B, et al. Antioxidant phytochemicals against type 2 diabetes. Br J Nutr 2008;99 E(Suppl 1):ES109-17
3. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3(10):768-80
4. Aruoma OI, Bahorun T, Jen L-S. Neuroprotection by bioactive components in medicinal and food plant extracts. Mutat ResRev Mutat Res 2003;544(2-3):203-15 (Pubitemid 37487662)
5. Zhou S, Gao Y, Jiang W, et al. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003;35(1):35-98 (Pubitemid 36249785)
6. Li Y, Revalde JL, Reid G, et al. Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. Drug Metab Rev 2010;42(4):590-611
7. Alvarez AI, Real R, Perez M, et al. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci 2010;99(2):598-617
8. Petri N, Tannergren C, Holst B, et al. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab Dispos 2003;31(6):805-13 (Pubitemid 36617672)
9. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol in vitro 2006;20(2):187-210 (Pubitemid 43087702)
10. Brand W, Schutte ME, Williamson G, et al. Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed Pharmacother 2006;60(9):508-19 (Pubitemid 44635082)
11. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92 (Pubitemid 34800230)
12. Faber KN, Muller M, Jansen PL. Drug transport proteins in the liver. Adv Drug Deliv Rev 2003;55(1):107-24 (Pubitemid 36082884)
13. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006;27(5):425-46 (Pubitemid 43363338)
14. Sarkadi B, Homolya L, Szakacs G, et al. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 2006;86(4):1179-236 (Pubitemid 44521651)
15. Stanley LA, Horsburgh BC, Ross J, et al. Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior. Drug Metab Rev 2009;41(1):27-65
16. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5(3):219-34 (Pubitemid 43336035)
17. Xia C, Smith PG. Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation. Mol Pharmacol 2012;82(6):1008-21
18. Pietta PG. Flavonoids as antioxidants. J Nat Prod 2000;63(7):1035-42
19. Harborne JB, Williams CA. Advances in flavonoid research since 1992. Phytochemistry 2000;55(6):481-504
20. Ignat I, Stingu A, Volf I, et al. Characterization of grape seed aqueous extract and possible applications in biological systems. Cellulose Chem Technol 2011;45(3-4):205-9
21. Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 2002;96(2-3):67-202 (Pubitemid 35356564)
22. Walle T, Browning AM, Steed LL, et al. Flavonoid glucosides are hydrolyzed and thus activated in the oral cavity in humans. J Nutr 2005;135(1):48-52 (Pubitemid 40094319)
23. Hollman PC, Bijsman MN, van Gameren Y, et al. The sugar moiety is a major determinant of the absorption of dietary flavonoid glycosides in man. Free Radic Res 1999;31(6):569-73
24. Hollman PC, de Vries JH, van Leeuwen SD, et al. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 1995;62(6):1276-82
25. Walle T, Otake Y, Walle UK, et al. Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr 2000;130(11):2658-61
26. Day AJ, Canada FJ, Diaz J. C, et al. Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett 2000;468(2-3):166-70 (Pubitemid 30110789)
27. Chen J, Lin H, Hu M. Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J Pharmacol Exp Ther 2003;304(3):1228-35 (Pubitemid 36254436)
28. Li Y, Lu J, Paxton JW. The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phytochemicals and their interactions with xenobiotics. Curr Drug Metab 2012;13(5):624-39
29. Lewis DF, Ito Y. Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme-substrate interactions. Expert Opin Drug Metab Toxicol 2008;4(9):1181-6
30. Lambert JD, Sang S, Yang CS. Biotransformation of green tea polyphenols and the biological activities of those metabolites. Mol Pharm 2007;4(6):819-25
31. Yang CS, Lambert JD, Ju J, et al. Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol Appl Pharmacol 2007;224(3):265-73 (Pubitemid 47592860)
32. Janisch KM, Williamson G, Needs P, et al. Properties of quercetin conjugates: modulation of LDL oxidation and binding to human serum albumin. Free Radic Res 2004;38(8):877-84 (Pubitemid 39077375)
33. Zhang L, Zuo Z, Lin G. Intestinal and hepatic glucuronidation of flavonoids. Mol Pharm 2007;4(6):833-45
34. Lotsch J, Geisslinger G. Morphine-6-glucuronide: an analgesic of the future? Clin Pharmacokinet 2001;40(7):485-99 (Pubitemid 32738656)
35. Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44(5):467-94 (Pubitemid 40733733)
36. Suri S, Taylor MA, Verity A, et al. A comparative study of the effects of quercetin and its glucuronide and sulfate metabolites on human neutrophil function in vitro. Biochem Pharmacol 2008;76(5):645-53
37. Day AJ, Bao Y, Morgan MR, et al. Conjugation position of quercetin glucuronides and effect on biological activity. Free Radic Biol Med 2000;29(12):1234-43
38. O'Leary KA, Day AJ, Needs PW, et al. Metabolism of quercetin-7-and quercetin-3-glucuronides by an in vitro hepatic model: the role of human beta-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (MRP2) in flavonoid metabolism. Biochem Pharmacol 2003;65(3):479-91 (Pubitemid 36084565)
39. Shimoi K, Saka N, Nozawa R, et al. Deglucuronidation of a flavonoid, luteolin monoglucuronide, during inflammation. Drug Metab Dispos 2001;29(12):1521-4 (Pubitemid 33111582)
40. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9(3):215-36
41. Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat Rev Mol Cell Biol 2009;10(3):218-27
42. Jones PM, George AM. The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 2004;61(6):682-99 (Pubitemid 38446412)
43. Higgins CF, Linton KJ. The ATP switch model for ABC transporters. Nat Struct Mol Biol 2004;11(10):918-26 (Pubitemid 39315294)
44. Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 2006;78(18):2116-30
45. Zhang W, Tan TM, Lim LY. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos 2007;35(1):110-15 (Pubitemid 46036483)
46. Shimabuku AM, Nishimoto T, Ueda K, et al. P-glycoprotein. ATP hydrolysis by the N-terminal nucleotide-binding domain. J Biol Chem 1992;267(7):4308-11
47. Soldner A, Benet L, Mutschler E, et al. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers. Br J Pharmacol 2000;129(6):1235-43 (Pubitemid 30153981)
48. Gifford AJ, Kavallaris M, Madafiglio J, et al. P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. Int J Cancer 1998;78(2):176-81 (Pubitemid 28443174)
49. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8
50. Cordon-Cardo C, O'Brein J, Casals D. Multidrug-resistance gene product (Pglycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-8 (Pubitemid 19037807)
51. Ichikawa M, Yoshimura A, Sumizawa T, et al. Interaction of organic chemicals with P-glycoprotein in the adrenal gland, kidney, and a multidrug-resistant KB cell. J Bio Chem 1991;266(2):903-8 (Pubitemid 21907201)
52. Jodoin J, Demeule M, Beliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 2002;1542(1-3):149-59
53. Zhang S, Morris ME. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 2003;20(8):1184-91 (Pubitemid 36951843)
54. de Wet H, McIntosh DB, Conseil G, et al. Sequence requirements of the ATP-binding site within the C-terminal nucleotide-binding domain of mouse Pglycoprotein: structure-activity relationships for flavonoid binding. Biochemistry (Mosc) 2001;40(34):10382-91 (Pubitemid 32800145)
55. Conseil G, Baubichon-Cortay H, Dayan G, et al. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP-and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 1998;95(17):9831-6
56. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003;304(3):1258-67 (Pubitemid 36254439)
57. Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 1997;250(1):130-7 (Pubitemid 27504592)
58. Tran VH, Marks D, Duke RK, et al. Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions. Nutr Cancer 2011;63(3):435-43
59. Rumsby M, Drew L, Warr J. Protein kinases and multidrug resistance. Cytotechnology 1998;27(1-3):203-24 (Pubitemid 29025470)
60. Mitsunaga Y, Takanaga H, Matsuo H, et al. Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur J Pharmacol 2000;395(3):193-201 (Pubitemid 30254368)
61. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95(26):15665-70 (Pubitemid 29018757)
62. Sarkadi B, Ozvegy-Laczka C, Nemet K, et al. ABCG2-a transporter for all seasons. FEBS Lett 2004;567(1):116-20
63. Jonker JW, Merino G, Musters S, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 2005;11(2):127-9 (Pubitemid 40321346)
64. Dreiseitel A, Oosterhuis B, Vukman KV, et al. Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. Br J Pharmacol 2009;158(8):1942-50
65. Imai Y, Tsukahara S, Asada S, et al. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 2004;64(12):4346-52 (Pubitemid 38802442)
66. Zhang SZ, Yang XN, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 2004;65(5):1208-16 (Pubitemid 38543491)
67. Cooray HC, Janvilisri T, van Veen HW, et al. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 2004;317(1):269-75 (Pubitemid 38401995)
68. Zhang S, Yang X, Morris ME. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 2004;21(7):1263-73 (Pubitemid 38954213)
69. Ebert B, Seidel A, Lampen A. Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol Sci 2007;96(2):227-36 (Pubitemid 46436705)
70. An G, Gallegos J, Morris ME. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. Drug Metab Dispos 2011;39(3):426-32
71. Sim HM, Wu CP, Ambudkar SV, et al. In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs. Biochem Pharmacol 2011;82(11):1562-71
72. Giri N, Agarwal S, Shaik N, et al. Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos 2009;37(3):560-70
73. Ejendal KFK, Hrycyna CA. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. Mol Pharmacol 2005;67(3):902-11 (Pubitemid 40365337)
74. Xia CQ, Liu N, Miwa GT, et al. Interactions of Cyclosporin A with breast cancer resistance protein. Drug Metab Dispos 2007;35(4):576-82.dmd.106.011866 (Pubitemid 46513259)
75. Zhang S, Yang X, Coburn RA, et al. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 2005;70(4):627-39 (Pubitemid 40978553)
76. Borst P, de Wolf C, van de Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch 2007;453(5):661-73
77. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4 (Pubitemid 23012438)
78. Cherrington NJ, Hartley DP, Li N, et al. Organ distribution of multidrug resistance proteins 1, 2, and 3 (mrp1, 2, and 3) mRNA and hepatic induction of mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 2002;300(1):97-104 (Pubitemid 34028514)
79. Kavallaris M. The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anticancer Drugs 1997;8:17-25 (Pubitemid 27064745)
80. Borst P, Evers R, Kool M, et al. A family of drug transporters: the multidrug resistance-associated proteins. J Nat Cancer Inst. 2000;92(16):1295-302 (Pubitemid 30662093)
81. Cullen KV, Davey RA, Davey MW. Verapamil-stimulated glutathione transport by the multidrug resistance-associated protein (MRP1) in leukaemia cells. Biochem Pharm 2001;62(4):417-24 (Pubitemid 32607723)
82. Borst P, Zelcer N, van de Wetering K, et al. On the putative co-transport of drugs by multidrug resistance proteins. FEBS Lett 2006;580(4):1085-93 (Pubitemid 43185288)
83. Versantvoort CH, Rhodes T, Twentyman PR. Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br J Cancer 1996;74(12):1949-54 (Pubitemid 27007140)
84. Leslie EM, Mao Q, Oleschuk CJ, et al. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol Pharmacol 2001;59(5):1171-80 (Pubitemid 32381597)
85. van Zanden JJ, Wortelboer HM, Bijlsma S, et al. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol 2005;69(4):699-708
86. Trompier D, Baubichon-Cortay H, Chang XB, et al. Multiple flavonoid-binding sites within multidrug resistance protein MRP1. Cell Mol Life Sci 2003;60(10):2164-77 (Pubitemid 37357424)
87. Leslie EM, Deeley RG, Cole SP. Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metab Dispos 2003;31(1):11-15 (Pubitemid 36735252)
88. Nguyen H, Zhang S, Morris ME. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 2003;92(2):250-7 (Pubitemid 36169297)
89. Cui Y, Konig J, Buchholz JK, et al. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999;55:929-37 (Pubitemid 29214613)
90. Konig J, Nies AT, Cui Y, et al. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999;1461(2):377-94
91. Borst P, Zelcer N, van de Wetering K. MRP2 and 3 in health and disease. Cancer Lett 2006;234(1):51-61 (Pubitemid 43343940)
92. Ishikawa T, Bao J, Yamane Y, et al. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Bio Chem 1996;271(25):14981-8 (Pubitemid 26197576)
93. van Zanden JJ, de Mul A, Wortelboer HM, et al. Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin. Biochem Pharmacol 2005;69(11):1657-65 (Pubitemid 40719501)
94. Aszalos A. Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs. Curr Drug Metab 2008;9(10):1010-18
95. Gan LS, Moseley MA, Khosla B, et al. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 1996;24(3):344-9
96. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997;27(2-3):161-70 (Pubitemid 27417871)
97. Kim KA, Park PW, Park JY. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur J Clin Pharmacol 2009;65(6):609-14
98. Mitsunaga Y, Takanaga H, Matsuo H, et al. Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur J Pharmacol 2000;395(3):193-201 (Pubitemid 30254368)
99. Choi JS, Choi HK, Shin SC. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int J Pharm 2004;275(1-2):165-70
100. Choi JS, Shin SC. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. Int J Pharm 2005;292(1-2):149-56
101. Choi JS, Jo BW, Kim YC. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 2004;57(2):313-18
102. Li X, Yun JK, Choi JS. Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos 2007;28(3):151-6 (Pubitemid 46730923)
103. Lim SC, Choi JS. Effects of naringin on the pharmacokinetics of intravenous paclitaxel in rats. Biopharm Drug Dispos 2006;27(9):443-7
104. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993;35(4):431-6 (Pubitemid 23103386)
105. Ho PC, Saville DJ, Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 2001;4(3):217-27 (Pubitemid 34305597)
106. Cermak R, Wolffram S. The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Curr Drug Metab 2006;7(7):729-44 (Pubitemid 44509679)
107. Pal D, Mitra AK. MDR-and CYP3A4-mediated drug-herbal interactions. Life Sci 2006;78(18):2131-45
108. Kawashiro T, Yamashita K, Zhao XJ, et al. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 1998;286(3):1294-300 (Pubitemid 29135542)
109. Wang YH, Chao PD, Hsiu SL, et al. Lethal quercetin-digoxin interaction in pigs. Life Sci 2004;74(10):1191-7
110. Taipalensuu J, Tornblom H, Lindberg G, et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 2001;299(1):164-70 (Pubitemid 32905131)
111. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61(8):3458-64 (Pubitemid 32695041)
112. Zimmermann C, Gutmann H, Hruz P, et al. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos 2005;33(2):219-24 (Pubitemid 40216589)
113. Englund G, Rorsman F, Ronnblom A, et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 2006;29(3-4):269-77 (Pubitemid 44602404)
114. Gutmann H, Hruz P, Zimmermann C, et al. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol 2005;70(5):695-9 (Pubitemid 41058704)
115. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002;99(24):15649-54 (Pubitemid 35403986)
116. Jia X, Chen J, Lin H, et al. Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J Pharmacol Exp Ther 2004;310(3):1103-13 (Pubitemid 39108932)
117. Zhang S, Sagawa K, Arnold RD, et al. Interactions between the flavonoid biochanin A and P-glycoprotein substrates in rats: in vitro and in vivo. J Pharm Sci 2010;99(1):430-41
118. Li X, Choi JS. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. Int J Pharm 2007;337(1-2):188-93 (Pubitemid 46756050)
119. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71(1):11-20 (Pubitemid 34124034)
120. Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol 2011;70(5):645-55
121. Wang X, Wolkoff AW, Morris ME. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 2005;33(11):1666-72 (Pubitemid 41539965)
122. Wong CC, Botting NP, Orfila C, et al. Flavonoid conjugates interact with organic anion transporters (OATs) and attenuate cytotoxicity of adefovir mediated by organic anion transporter 1 (OAT1/SLC22A6). Biochem Pharmacol 2011;81(7):942-9
123. Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 2004;65(5):1208-16 (Pubitemid 38543491)
124. Sesink AL, Arts IC, de Boer VC, et al. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol Pharmacol 2005;67(6):1999-2006 (Pubitemid 41007781)
125. Imai Y, Asada S, Tsukahara S, et al. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 2003;64(3):610-18 (Pubitemid 37048564)
126. An G, Morris ME. The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2). Biopharm Drug Dispos 2011;32(8):446-57
127. Wang X, Morris ME. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos 2007;35(2):268-74 (Pubitemid 46148740)
128. Lee YJ, Kusuhara H, Jonker JW, et al. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 2005;312(1):44-52 (Pubitemid 40096451)
129. Enokizono J, Kusuhara H, Sugiyama Y. Effect of breast cancer resistance protein (bcrp/abcg2) on the disposition of phytoestrogens. Mol Pharmacol 2007;72(4):967-75 (Pubitemid 47481419)
130. Shukla S, Zaher H, Hartz A, et al. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res 2009;26(2):480-7
131. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000;92(20):1651-6
132. Evseenko DA, Paxton JW, Keelan JA. ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am J Physiol Regul Integr Comp Physiol 2006;290(5):R1357-65
133. Merino G, Jonker JW, Wagenaar E, et al. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 2005;67(5):1758-64 (Pubitemid 40594177)
134. van Zanden JJ, van der Woude H, Vaessen J, et al. The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential. Biochem Pharmacol 2007;74(2):345-51 (Pubitemid 46890811)
135. Jager W, Gehring E, Hagenauer B, et al. The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy. Int J Clin Pharmacol Ther 2003;41(12):610-11
136. Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 2001;12(4):361-7 (Pubitemid 32166734)
137. De Castro WV, Mertens-Talcott S, Derendorf H, et al. Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats. J Agric Food Chem 2008;56(12):4840-5 (Pubitemid 351999419)
138. Shirasaka Y, Li Y, Shibue Y, et al. Concentration-dependent effect of naringin on intestinal absorption of b1-adrenoceptor antagonist talinolol mediated by P-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res 2009;26(3):560-7
139. Schwarz UI, Seemann D, Oertel R, et al. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther 2005;77(4):291-301 (Pubitemid 40470385)
140. Becquemont L, Verstuyft C, Kerb R, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001;70(4):311-16 (Pubitemid 33022471)
141. Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 2003;33:10-16 (Pubitemid 37421611)
142. Kamath AV, Ming Y, Zhang YP, et al. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci 2005;94(2):233-9 (Pubitemid 40293320)
143. Banfield C, Gupta S, Marino M, et al. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 2002;41(4):311-18 (Pubitemid 34533758)
144. Park JH, Hur HJ, Woo JS, et al. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2012;45(3):296-301
145. Bansal T, Awasthi A, Jaggi M, et al. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein. Life Sci 2008;83(7-8):250-9
146. Li C, Choi JS. Effects of epigallocatechin gallate on the bioavailability and pharmacokinetics of diltiazem in rats. Pharmazie 2008;63(11):815-18
147. Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999;65:237-44 (Pubitemid 29142929)
148. Mols R, Deferme S, Augustijns P. Sulfasalazine transport in in-vitro ex-vivo and in-vivo absorption models: contribution of efflux carriers and their modulation by co-administration of synthetic nature-identical fruit extracts. J Pharm Pharmacol 2005;57(12):1565-73 (Pubitemid 41752270)
149. Kusuhara H, Furuie H, Inano A, et al. Pharmacokinetic interaction study of sulfasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. Br J Pharmacol 2012;166(6):1793-803
150. Moon YJ, Morris ME. Pharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in rats. Mol Pharm 2007;4(6):865-72
151. Zhang S, Wang X, Sagawa K, et al. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b mice. Drug Metab Dispos 2005;33(3):341-8 (Pubitemid 40279933)
152. An G, Morris ME. Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo. Biopharm Drug Dispos 2010;31(5-6):340-50
153. An G, Wu F, Morris ME. 5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice. Pharm Res 2011;28(5):1090-9